News

The dose-finding study was a randomized, placebo-controlled, double-blind, multicenter, multinational clinical trial that evaluated the efficacy and safety of four different doses (one, two, five or 10mg BID)

As part of its long-term commitment to hepatitis C therapy, Schering-Plough is developing SCH 900518 (518), a next-generation hepatitis C virus (HCV) protease inhibitor. A Phase IIa study

The company has also requested priority review of its application and, if granted, Clolar could be approved for this indication in the first half of 2009. Genzyme’s supplemental

Most recently, Mr Pinon was CEO of Bioheart, a biotechnology company focused on the development of heart failure therapies and devices. Prior to Bioheart, Mr Pinon held a

Labopharm’s new drug application (NDA) for its novel trazodone formulation is based on data from five pivotal pharmacokinetic studies and the positive results from its North American Phase

Mr Vaello brings more than 15 years of sales expertise in the oncology and imaging industries to TomoTherapy, where he will be responsible for enhancing sales performance and

Previously, Mr King has served as the CEO of Principia Pharmaceutical, which was acquired by Human Genome Sciences, and as president of Delsys Pharmaceutical, which was acquired by

The Phase Ib clinical trial is designed to primarily evaluate the safety and tolerability of repeated dosing of MDX-1106 in adult patients with solid tumors and will also

Similar to the treatment week 12 results reported earlier in 2008, the 48-week viral response data continue to show comparable reductions in viral load for weight-based doses of